Capricor Therapeutics, Inc.
CAPR
$8.64
-$0.42-4.64%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 30.93% | 44.73% | 58.93% | 72.42% | 76.31% |
| Gross Profit | -30.93% | -44.73% | -575.53% | -113.27% | -158.37% |
| SG&A Expenses | 148.30% | 54.86% | 41.00% | 71.06% | 85.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.94% | 47.19% | 54.86% | 72.11% | 78.10% |
| Operating Income | -54.94% | -47.19% | -278.84% | -102.03% | -139.13% |
| Income Before Tax | -57.21% | -39.15% | -324.02% | -95.68% | -135.54% |
| Income Tax Expenses | 0.00% | -- | 0.00% | -- | -- |
| Earnings from Continuing Operations | -57.21% | -39.15% | -323.95% | -95.68% | -135.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.21% | -39.15% | -323.95% | -95.68% | -135.56% |
| EBIT | -54.94% | -47.19% | -278.84% | -102.03% | -139.13% |
| EBITDA | -55.64% | -47.44% | -291.41% | -103.89% | -142.39% |
| EPS Basic | -24.04% | -10.57% | -286.24% | -41.63% | -64.13% |
| Normalized Basic EPS | -24.05% | -10.99% | -292.68% | -41.57% | -64.10% |
| EPS Diluted | -24.04% | -10.57% | -286.24% | -41.63% | -64.13% |
| Normalized Diluted EPS | -24.05% | -10.99% | -292.68% | -41.57% | -64.10% |
| Average Basic Shares Outstanding | 26.73% | 25.85% | 9.75% | 38.16% | 43.55% |
| Average Diluted Shares Outstanding | 26.73% | 25.85% | 9.75% | 38.16% | 43.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |